This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
The Relationship Between Novel Virological Indicators and Treatment With Different Nucleotide Analogues and the Prognosis of HBV-ACLF Patients | MicrobiomeTrials
← Back to trials NCT07815418
The Relationship Between Novel Virological Indicators and Treatment With Different Nucleotide Analogues and the Prognosis of HBV-ACLF Patients Completed OBSERVATIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2022-02-01Est. Completion: 2024-04-01
Enrollment target: 235 participantsLocations Tongji Hospital, Wuhan, Hubei, China Other microbiome trials you might be interested in Acute-On-Chronic Liver Failure Sepsis
This study aims to evaluate the efficacy and safety of the double plasma cytokine adsorption system with sequential low-…
Guangzhou, China Est. completion Oct 31, 2027
Liver Cirrhosis Decompensated Cirrhosis of Liver Acute on Chronic Liver Failure (ACLF)
The goal of this clinical trial is to determine primarily whether a combinatorial therapy based on the administration of…
Clichy, France Est. completion Oct 31, 2026